drugset / Trial / NCT06301828

Endostar Combined With SBRT and Envafolimab in the Treatment of Advanced Gastrointestinal Tumors

NCT06301828

NaSingle-groupOpen-labelTreatment

Summary

This is a single-arm, prospective, exploratory clinical study to evaluate the efficacy and safety of endostar combined with stereotactic body radiation therapy (SBRT) and Envafolimab in patients with advanced gastrointestinal cancer after multi-line treatment.

Timeline

Start
2024-02-21
Primary completion
2025-06-21
Completion
2026-02-21

Drugs

EvaluationDrugModalityDoseRoute
Subject Endostar Protein / enzyme biologic
Subject Envafolimab Monoclonal antibody